Trevi Therapeutics' (TRVI) "Buy" Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI - Free Report) in a research report sent to investors on Friday,Benzinga reports. They currently have a $8.00 target price on the stock.

A number of other research firms also recently weighed in on TRVI. HC Wainwright restated a "buy" rating and set a $6.00 price target on shares of Trevi Therapeutics in a report on Tuesday, October 22nd. Raymond James initiated coverage on Trevi Therapeutics in a report on Friday, August 30th. They issued an "outperform" rating and a $9.00 price target for the company. B. Riley reissued a "buy" rating and issued a $6.00 price target on shares of Trevi Therapeutics in a report on Monday, October 7th. Leerink Partners began coverage on Trevi Therapeutics in a research note on Monday, September 9th. They set an "outperform" rating and a $7.00 price target on the stock. Finally, Leerink Partnrs raised shares of Trevi Therapeutics to a "strong-buy" rating in a research note on Monday, September 9th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $7.43.

Trevi Therapeutics Price Performance

Shares of TRVI traded up $0.01 during trading hours on Friday, reaching $2.91. 601,003 shares of the company's stock traded hands, compared to its average volume of 285,322. The firm has a market capitalization of $211.24 million, a price-to-earnings ratio of -6.59 and a beta of 1.01. The business's fifty day simple moving average is $3.15 and its two-hundred day simple moving average is $2.91. Trevi Therapeutics has a twelve month low of $0.97 and a twelve month high of $4.00.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.01). During the same quarter last year, the firm posted ($0.07) earnings per share. On average, equities research analysts expect that Trevi Therapeutics will post -0.47 EPS for the current year.

Insider Activity

In related news, CEO Jennifer L. Good sold 10,981 shares of the business's stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total value of $33,162.62. Following the sale, the chief executive officer now directly owns 213,313 shares of the company's stock, valued at approximately $644,205.26. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, insider Thomas Sciascia sold 18,660 shares of the company's stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $2.76, for a total transaction of $51,501.60. Following the sale, the insider now owns 220,315 shares in the company, valued at approximately $608,069.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Jennifer L. Good sold 10,981 shares of the firm's stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total value of $33,162.62. Following the completion of the transaction, the chief executive officer now owns 213,313 shares of the company's stock, valued at approximately $644,205.26. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,355 shares of company stock worth $116,663 over the last quarter. 24.37% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Trevi Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of TRVI. Ally Bridge Group NY LLC acquired a new position in Trevi Therapeutics during the second quarter worth approximately $4,395,000. Logos Global Management LP boosted its position in Trevi Therapeutics by 27.3% during the second quarter. Logos Global Management LP now owns 2,800,000 shares of the company's stock worth $8,344,000 after purchasing an additional 600,000 shares during the period. Rosalind Advisors Inc. raised its position in shares of Trevi Therapeutics by 50.3% in the second quarter. Rosalind Advisors Inc. now owns 1,391,577 shares of the company's stock valued at $4,147,000 after purchasing an additional 465,561 shares during the period. Propel Bio Management LLC acquired a new stake in shares of Trevi Therapeutics during the 1st quarter worth about $897,000. Finally, GSA Capital Partners LLP acquired a new position in Trevi Therapeutics in the 3rd quarter valued at about $409,000. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.